Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Vida Ventures

Investor type Venture Capital
Founders Arie Belldegrun Arjun Goyal Fred Cohen Len Potter Stefan Vitorovic

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 44
Average round size
info
The average size of a deal this fund participated in
$98M
Portfolio companies 33
Rounds per year 8.80
Lead investments 10
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.25
Exits 11
Key employees 4
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2017 was created Vida Ventures, which is appeared as VC. The venture was found in North America in United States. The leading representative office of defined VC is situated in the Boston.

This organization was formed by Arjun Goyal, Len Potter, Stefan Vitorovic. Besides them, we counted 4 critical employees of this fund in our database.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Vida Ventures, startups are often financed by SV Health Investors, Skyline Ventures, Amgen Ventures. The meaningful sponsors for the fund in investment in the same round are Nextech Invest, OrbiMed, The Column Group. In the next rounds fund is usually obtained by Perceptive Advisors, Nextech Invest, venBio Select Advisor.

Among the most popular portfolio startups of the fund, we may highlight Allogene Therapeutics, Pionyr Immunotherapeutics, Kronos Bio. The fund has no exact preference in some founders of portfolio startups. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Biotechnology, Medical Device. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.

The important activity for fund was in 2019. The fund is generally included in 2-6 deals every year. The common things for fund are deals in the range of more than 100 millions dollars. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations. The increased amount of exits for fund were in 2018. This Vida Ventures works on 4 percentage points more the average amount of lead investments comparing to the other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Vida Ventures:
Typical Co-investors
Vida Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Vida Ventures:

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
ARCO/Murray Design Build -
Ashe Partners -
Guochuang Medical China, Shanghai
Hanmi Pharmaceutical Seoul, Seoul-t'ukpyolsi, South Korea
Intouch Holdings PCL Bangkok, Krung Thep, Thailand
Kakao Brain Kyonggi-do, Seongnam, South Korea
Loreda Holdings -
Medinet Co Ishinomaki, Japan, Miyagi Prefecture
MS & Consulting Japan, Tokyo
National Renewable Energy Laboratory Colorado, Golden, United States
Orange Digital Ventures France, Ile-de-France, Paris
PoliHub Italy, Lombardia, Milano
QBE Insurance Group Australia, New South Wales, Sydney
Rainforest Venture Network Delhi, India, New Delhi
Slaughter and May England, London, United Kingdom
Tahoe Venture China, Jiangsu, Suzhou
TBT Seoul, Seoul-t'ukpyolsi, South Korea
TrueSight Ventures England, London, United Kingdom
Z Nation Lab India, Maharashtra, Mumbai

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Alterome Therapeutics

Biopharma
Pharmaceutical
$35M02 Nov 2022 San Diego, California, United States

Capstan Therapeutics

Biotechnology
Health Care
Therapeutics
$102M14 Sep 2022 San Diego, California, United States

Aktis Oncology

Biotechnology
Life Science
$84M25 Aug 2022 Boston, Massachusetts, United States

Affini-T Therapeutics

Biotechnology
Health Care
Therapeutics
$175M22 Mar 2022 Watertown, Massachusetts, United States

Kyverna Therapeutics

Biotechnology
Life Science
Therapeutics
$85M26 Jan 2022 Berkeley, California, United States

Alterome Therapeutics

Biopharma
Pharmaceutical
$64M19 Jan 2022 San Diego, California, United States

Capstan Therapeutics

Biotechnology
Health Care
Therapeutics
$63M01 Nov 2021 San Diego, California, United States

Quanta Therapeutics

Biotechnology
Health Care
Medical Device
Therapeutics
$60M26 Oct 2021 San Francisco, California, United States

ReCode Therapeutics

Biopharma
Biotechnology
Health Care
Pharmaceutical
Wellness
$80M21 Oct 2021 Dallas, Texas, United States
News
ReCode Therapeutics Raises Oversubscribed Series B Financing Round of $80 Million

– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

Vigil Neuroscience Completes $90 million Series B Financing to Advance a Pipeline of Microglia-targeted Medicines to Treat Rare and Common Neurodegenerative Diseases

– Vigil Neuroscience, a biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, announced the completion of a $90m Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration.
– The financing was led by Vida Ventures with participation from existing investors Atlas Venture, Northpond Ventures and Hatteras Venture Partners as well as new investors including Surveyor Capital (a Citadel company), Cormorant Asset Management, Invus, OrbiMed, Rock Springs Capital, Deep Track Capital, Logos Capital, Pivotal bioVenture Partners, and Lightstone Ventures.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Vida Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: